WO2014077383A1 - Agent destiné à améliorer l'allergie - Google Patents

Agent destiné à améliorer l'allergie Download PDF

Info

Publication number
WO2014077383A1
WO2014077383A1 PCT/JP2013/081016 JP2013081016W WO2014077383A1 WO 2014077383 A1 WO2014077383 A1 WO 2014077383A1 JP 2013081016 W JP2013081016 W JP 2013081016W WO 2014077383 A1 WO2014077383 A1 WO 2014077383A1
Authority
WO
WIPO (PCT)
Prior art keywords
allergy
galactopyranosyl
galactooligosaccharide
ameliorating
agent
Prior art date
Application number
PCT/JP2013/081016
Other languages
English (en)
Japanese (ja)
Inventor
松山　博昭
聡志 日暮
加藤　健
誠一郎 青江
Original Assignee
雪印メグミルク株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 雪印メグミルク株式会社 filed Critical 雪印メグミルク株式会社
Priority to CN201380060243.8A priority Critical patent/CN104797260A/zh
Publication of WO2014077383A1 publication Critical patent/WO2014077383A1/fr
Priority to HK15108025.5A priority patent/HK1207311A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/14—Pretreatment of feeding-stuffs with enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients

Definitions

  • the present invention relates to an allergy ameliorating agent. More specifically, the present invention relates to an allergy ameliorating agent that is excellent in allergy improving action, suppresses metabolic inflammation, and suppresses secretion of inflammatory cytokines, thereby improving disturbance of the immune regulatory system in the living body.
  • the present invention further relates to an allergy ameliorating food / beverage, an allergy ameliorating nutritional composition, an allergy ameliorating feed or an allergy ameliorating pharmaceutical, which further contains an allergy ameliorating agent.
  • helper T cells There are two types of helper T cells: helper T1 (hereinafter referred to as “Th1”) cells and helper T2 (hereinafter referred to as “Th2”) cells.
  • Th1 helper T1
  • Th2 helper T2
  • cytokines cytokines produced by each and maintain a balance
  • an increase in inflammatory markers such as F4 / 80
  • NADPH oxidase subunits such as P40phox
  • secretion is promoted and allergic symptoms are thought to be induced. Therefore, it is possible to improve allergic diseases by suppressing the increase of inflammatory markers such as NADPH oxidase and macrophages and suppressing the secretion of inflammatory cytokines.
  • Antihistamines and steroids are known as drugs for allergic diseases.
  • these medicines may have side effects such as tinnitus, headache, and loss of appetite.
  • these substances cannot be added to food and drink at present from the viewpoints of safety and cost.
  • desensitization therapies that gradually weaken the response by administering a small amount of allergen for a long time, diets to avoid contact with allergens, etc. These include the need for long-term treatment and life Since there is a problem such as a decrease in quality (QOL), as an easy method, development of food and drink and feed that can be expected to prevent or treat allergic diseases by ingestion is desired.
  • QOL decrease in quality
  • Indigestible oligosaccharides flavonoids, polyunsaturated fatty acids, etc. are known as food ingredients that improve allergic symptoms. Indigestible oligosaccharides are said to be effective in maintaining the normal state of intestinal flora mainly composed of bifidobacteria, and the Th1 environment is induced by ingestion of raffinose, an indigestible oligosaccharide. It is known that the Th2 response of the systemic immune system is suppressed. In addition, acidic xylo-oligosaccharides have been shown to suppress inflammatory cytokines, and ingestion of oligosaccharides is considered to have an effect on allergy suppression from various aspects.
  • An object of the present invention is to provide an allergy ameliorating agent that improves the disturbance of the immune regulatory system in the living body by suppressing the secretion of inflammatory cytokines.
  • the inventors of the present invention have made extensive studies to solve the above problems, O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 4)]-D-glucose or O- ⁇ -D-galactopyranosyl- (1 ⁇ 4)-[O
  • the present inventors have found that galactooligosaccharides having the structural formula represented by - ⁇ -D-galactopyranosyl- (1 ⁇ 6)]-D-glucose have an allergy ameliorating effect through suppression of inflammatory cytokine secretion. That is, the present invention includes the following modes.
  • an allergy ameliorating agent comprising a galactooligosaccharide having the structural formula represented by (2)
  • An allergy-improving food or drink, an allergy-improving nutritional composition, an allergy-improving feed, or an allergy-improving pharmaceutical comprising the allergy-improving agent according to any one of (1) to (3).
  • the allergy ameliorating agent of the present invention suppresses metabolic inflammation and suppresses secretion of inflammatory cytokines, thereby improving disturbance of the immune regulatory system in the living body.
  • the allergy ameliorating agent of the present application is O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 4)]-D-glucose or O- ⁇ -D-galactopyranosyl-
  • the active ingredient is a galactooligosaccharide having a structural formula represented by (1 ⁇ 4)-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)]-D-glucose.
  • the allergy ameliorating agent containing the galactooligosaccharide as an active ingredient suppresses the increase of inflammatory markers such as NADPH oxidase and macrophages and suppresses the secretion of inflammatory cytokines. Thereby, it is useful for prevention and / or treatment of various allergic diseases such as atopic dermatitis, allergic rhinitis, urticaria and hay fever. It is also useful for the prevention and / or treatment of rheumatism.
  • the galactooligosaccharide used in the improving agent described in the present application can be easily and economically produced because it uses lactose as a raw material, and because the sugar composition of the active ingredient is specified, it is safe.
  • O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 4)]-D-glucose or O- ⁇ -D-galactopyranosyl- (1 ⁇ 4) )-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)]-D-glucose is a galactooligosaccharide having a structural formula represented by, for example, Sumilacto LL in a solution containing 20% to 40% lactose.
  • the lactose-assimilating bacterium is main-cultured in a main culture medium having a lactose content of about 13% and a pH of 4 to 9, and then concentrated under reduced pressure to remove unreacted lactose from the culture solution, and further ⁇ -galactosidase acts.
  • the solution obtained by decomposing unreacted lactose remaining in the culture solution is passed through an activated carbon column, and the adsorbed galactooligosaccharide is eluted with 20% ethanol.
  • the main culture is cultured at 20 to 40 ° C., preferably around 30 ° C. for 5 to 15 days, the yield can be further increased.
  • the galactooligosaccharide prepared as described above can be concentrated by a reverse osmosis membrane (RO) membrane or the like, or dried by freeze drying or the like.
  • RO reverse osmosis membrane
  • Lactose used as a raw material for galactooligosaccharides is lactose prepared from milk from mammals such as cattle, goats, sheep, and humans, and aggregates, powders, or purified lactose, which are used to react with ⁇ -galactosidase. In the case of the main culture, it can be used in the state of an aqueous solution.
  • the above-described galactooligosaccharide may be used as it is as an allergy ameliorating agent, but if necessary, it is formulated into powders, granules, tablets, capsules, drinks, etc. according to conventional methods. It can also be used. Furthermore, galactooligosaccharides obtained by reverse osmosis membrane (RO) membrane treatment or the like can also be used as an allergy ameliorating agent as they are, and can be used as they are after drying. Moreover, it can also be formulated and used according to a conventional method. Furthermore, after formulating these, it is also possible to mix this with foods and beverages such as nutrients, yogurt, beverages, wafers, nutritional compositions, feeds and pharmaceuticals.
  • foods and beverages such as nutrients, yogurt, beverages, wafers, nutritional compositions, feeds and pharmaceuticals.
  • allergy improving food and beverage, allergic improving nutrition composition, allergy improving feed and allergy improving pharmaceutical include not only the active ingredient galactooligosaccharide, but also stabilizers, saccharides, lipids, Flavors, vitamins, minerals, flavonoids, polyphenols, and other raw materials usually contained in other foods, feeds and medicines can be contained. Further, in addition to the active ingredient galactooligosaccharide, it can also be used together with other components showing an allergy improving action, such as raffinose and acidic xylo-oligosaccharide. In addition, it may be prepared by blending raw materials usually contained in other foods and drinks, etc., using such allergy improving food and drink, allergy improving nutritional composition, allergy improving feed or allergy improving pharmaceuticals as raw materials. Is possible.
  • the compounding amount of galactooligosaccharides in allergic ameliorating foods, allergic ameliorating compositions, allergy ameliorating feeds, and allergy ameliorating pharmaceuticals is not particularly limited. Depending on the form of food, drink, feed and medicine, it generally contains 0.01 to 10% (mass / mass), preferably 0.1 to 5% (mass / mass) with respect to the total mass. Preferably it is.
  • the allergy ameliorating agent described in the present application can be formulated into an arbitrary form by adding an appropriate auxiliary agent to the above active ingredient, and can be made into an allergy ameliorating composition that can be administered orally.
  • diluents or excipients such as fillers, extenders, binders, disintegrants, surfactants, lubricants and the like that are usually used can be used.
  • excipient include sucrose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicic acid, magnesium aluminate, synthetic aluminum silicate, magnesium magnesium metasilicate, calcium carbonate, sodium hydrogen carbonate, calcium hydrogen phosphate
  • carboxymethylcellulose calcium and the like can be added in combination.
  • the present invention also relates to an allergy ameliorating method in which the allergy ameliorating agent of the above-described embodiment is orally ingested.
  • the allergy ameliorating method is useful for the treatment and / or prevention of various allergic diseases.
  • the allergy ameliorating method is effective for mammals such as humans as well as domestic animals such as dogs and cats.
  • Example 1 Commercially available ⁇ -galactosidase (trade name: Sumilac LL, Shin Nippon Chemical Industry Co., Ltd.) was added to 5000 ml of 20% lactose aqueous solution at 3 units / ml, and reacted at 40 ° C. (pH 5.0) for 3 hours. I let you. This solution is concentrated under reduced pressure to precipitate and remove lactose, and after passing through an activated carbon column (15 cm ⁇ 30 cm) to adsorb galactooligosaccharide, 3000 ml of 5% ethanol is passed through and remains. Lactose was removed.
  • galactooligosaccharide powder includes O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 4)]-D-glucose or O- ⁇ -D-galactopyranosyl- ( 12% by mass of galactooligosaccharide having a structural formula represented by 1 ⁇ 4)-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)]-D-glucose was contained.
  • the galactooligosaccharide thus obtained can be used as it is as an allergy ameliorating agent.
  • Penicillium roqueforti IFO 4135 strain was precultured (lactose 2.9%, dipotassium hydrogen phosphate 0.1%, magnesium sulfate heptahydrate 0.05%, sodium nitrate 0.2%, Potassium chloride 0.05%, iron sulfate 0.001%) was inoculated into 100 ml, and cultured at 30 ° C. for 5 days. 100 ml of the obtained preculture solution was added to the main culture medium (lactose 13%, dipotassium hydrogen phosphate 0.09%, magnesium sulfate heptahydrate 0.04%, sodium nitrate 0.17%, potassium chloride 0.04%).
  • This galactooligosaccharide powder includes O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 4)]-D-glucose or O- ⁇ -D-galactopyranosyl- ( 1 ⁇ 4)-[O- ⁇ -D-galactopyranosyl- (1 ⁇ 6)]-D-glucose contained 9% by mass of galactooligosaccharide having the structural formula.
  • the galactooligosaccharide thus obtained can be used as it is as an allergy ameliorating agent.
  • TNCB 2,4,6-trinitro-1-chlorobenzene
  • mice in Group A control
  • Group B mice in each group
  • mice in Group C mice in each group
  • Saccharide was orally administered at 50 mg / kg of mouse body weight
  • galactooligosaccharide of Example Product 2 was orally administered daily for 2 weeks over 2 weeks.
  • Example Products 1 and 2 suspended in physiological saline were orally administered.
  • the right ear of the mouse was removed and its mass was measured, and the expression level of the inflammatory marker (F4 / 80, P40phox) mRNA was measured by a real-time PCR method.
  • the results are shown in Table 1.
  • the right ear mass and the expression level of inflammatory marker (F4 / 80, P40phox) mRNA after 2 weeks of administration were 50 mg or more of the galactooligosaccharides of Examples 1 and 2 per 1 kg of mouse body weight.
  • the B and C groups were significantly lower than the A group (control). From these results, it was found that the galactooligosaccharides of Examples 1 and 2 had an allergy improving action. Moreover, it became clear that this effect
  • Example 3 Preparation of tablets for allergy improvement
  • Each raw material was mixed so that the total amount was 100.0 parts by mass with the formulation shown in Table 2, and then molded into 1 g by a conventional method and compressed to produce tablets for allergy improvement.
  • Example 4 (Preparation of liquid nutritional composition for allergy improvement) 50 g of the galactooligosaccharide of Example product 2 was dissolved in 4,950 g of deionized water, heated to 50 ° C., and then stirred at 6,000 rpm for 30 minutes with a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). By mixing, a galactooligosaccharide solution of Example Product 2 having a galactooligosaccharide content of 50 g / 5 kg was obtained.
  • TK ROBO MICS manufactured by Tokushu Kika Kogyo Co., Ltd.
  • Example 5 Preparation of beverage for allergy improvement
  • 300 g of skim milk powder in 409 g of deionized water 1 g of the galactooligosaccharide of Example product 1 was dissolved, heated to 50 ° C., and then with an ultradisperser (ULTRA-TURRAX-25; manufactured by IKA Japan). The mixture was stirred and mixed at 9,500 rpm for 30 minutes.
  • maltitol 100g, acidulant 2g, reduced starch syrup 20g, fragrance 2g, deionized water 166g it is filled into a 100ml glass bottle, sterilized at 95 ° C for 15 seconds, hermetically sealed, and 10 drinks for allergy improvement (100ml) Prepared).
  • Example 6 Preparation of allergy-improving feed for dogs 2 kg of the galactooligosaccharide of Example product 2 was dissolved in 98 kg of deionized water, heated to 50 ° C., and then stirred and mixed for 40 minutes at 3,600 rpm with a TK homomixer (MARK II 160 type; manufactured by Tokushu Kika Kogyo Co., Ltd.). Thus, a galactooligosaccharide solution of Example Product 2 having a galactooligosaccharide content of 2 g / 100 g was obtained.
  • TK homomixer MARK II 160 type

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un agent destiné à améliorer l'allergie et ayant pour effet d'inhiber la sécrétion d'une cytokine inflammatoire et, par suite, d'améliorer les troubles affectant le système immuno-régulateur in vivo, ainsi que des produits destinés à améliorer l'allergie, tels que des aliments, des boissons, des aliments pour animaux et des médicaments, lesdits produits contenant ledit agent destiné à améliorer l'allergie. L'invention concerne, donc, un agent destiné à améliorer l'allergie et contenant, en tant que principe actif, un galacto-oligosaccharide de formule développée : O-β-D-galactopyranosyl-(1→6)-[O-β-D-galactopyranosyl-(1→4)]-D-glucose ; ou O-β-D-galactopyranosyl-(1→4)-[O-β-D-galactopyranosyl-(1→6)]-D-glucose.
PCT/JP2013/081016 2012-11-19 2013-11-18 Agent destiné à améliorer l'allergie WO2014077383A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201380060243.8A CN104797260A (zh) 2012-11-19 2013-11-18 变态反应改善剂
HK15108025.5A HK1207311A1 (en) 2012-11-19 2015-08-19 Agent for ameliorating allergy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012253718A JP6072516B2 (ja) 2012-11-19 2012-11-19 アレルギー改善剤
JP2012-253718 2012-11-19

Publications (1)

Publication Number Publication Date
WO2014077383A1 true WO2014077383A1 (fr) 2014-05-22

Family

ID=50731291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/081016 WO2014077383A1 (fr) 2012-11-19 2013-11-18 Agent destiné à améliorer l'allergie

Country Status (6)

Country Link
JP (1) JP6072516B2 (fr)
CN (1) CN104797260A (fr)
HK (1) HK1207311A1 (fr)
MY (1) MY177993A (fr)
TW (1) TW201427603A (fr)
WO (1) WO2014077383A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016216393A (ja) * 2015-05-20 2016-12-22 再生ファーマ株式会社 アレルギー疾患の予防改善剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975095A1 (fr) * 2015-01-26 2016-08-04 Cadena Bio, Inc. Compositions a base d'oligosaccharides destinees a etre utilisees comme aliment pour animaux et procedes de production de celles-ci
US20210330710A1 (en) * 2018-09-05 2021-10-28 Saisei Pharma Co., Ltd. Inflammatory cytokine production inhibitor
DE102020133860A1 (de) 2020-12-16 2022-06-23 MNT Systeme GmbH VERWENDUNG VON β-GALAKTOOLIGOSACCHRIDEN FÜR DIE HERSTELLUNG EINER KOSMETISCHEN UND/ODER PHARMAKOLOGISCH WIRKSAMEN ZUSAMMENSETZUNG

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789976A (ja) * 1993-09-17 1995-04-04 Snow Brand Milk Prod Co Ltd 新規オリゴ糖
JP2000060541A (ja) * 1998-08-27 2000-02-29 Fuyuki Mitsuyama ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤
JP2006136240A (ja) * 2004-11-12 2006-06-01 Kumamoto Prefecture ビフィズス菌増殖促進性組成物
JP2008280354A (ja) * 2005-04-21 2008-11-20 Hokuren Federation Of Agricult Coop:The アレルギー抑制オリゴ糖

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4844922B2 (ja) * 2006-01-24 2011-12-28 日新製糖株式会社 アレルギー体質改善組成物
JP2009114080A (ja) * 2007-11-02 2009-05-28 Icreo Co Ltd アトピー性皮膚炎治療組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789976A (ja) * 1993-09-17 1995-04-04 Snow Brand Milk Prod Co Ltd 新規オリゴ糖
JP2000060541A (ja) * 1998-08-27 2000-02-29 Fuyuki Mitsuyama ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤
JP2006136240A (ja) * 2004-11-12 2006-06-01 Kumamoto Prefecture ビフィズス菌増殖促進性組成物
JP2008280354A (ja) * 2005-04-21 2008-11-20 Hokuren Federation Of Agricult Coop:The アレルギー抑制オリゴ糖

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016216393A (ja) * 2015-05-20 2016-12-22 再生ファーマ株式会社 アレルギー疾患の予防改善剤

Also Published As

Publication number Publication date
JP2014101305A (ja) 2014-06-05
JP6072516B2 (ja) 2017-02-01
TW201427603A (zh) 2014-07-16
HK1207311A1 (en) 2016-01-29
CN104797260A (zh) 2015-07-22
MY177993A (en) 2020-09-28

Similar Documents

Publication Publication Date Title
AU2001231746B2 (en) Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
EP1858340B1 (fr) Produit alimentaire comportant un probiotique et un beta-glucane isole et son procede d'utilisation
EP2420244B1 (fr) Agent améliorant le métabolisme des lipides
TW201429477A (zh) 使用人乳寡糖之用於調節炎症之營養調配物
AU2001231746A1 (en) Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
WO2013161820A1 (fr) Composition favorisant la croissance de bifidobacterium
CN101594789A (zh) 益生菌（婴儿）食品
EP3981255A1 (fr) Composition nutritionnelle
CN111903766A (zh) 一种婴幼儿配方奶粉及其制备方法
JP6072516B2 (ja) アレルギー改善剤
TW201208583A (en) Nutritional compositions
WO2017009676A1 (fr) Compositions de conservation et de reconstitution de symbiose microbiote-hôte
JP2024091698A (ja) 抗ストレス用組成物
JP2019513390A (ja) 食物、エネルギーおよび／または脂肪の摂取を減少させるためのビフィズス菌（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ）
JP5971949B2 (ja) 抗ウイルス剤
CN112806577B (zh) 产丁酸的益生元益生菌增效组合
WO2014163031A1 (fr) Régulateur intestinal instantané
JP2004236589A (ja) ペプチドミルク
JP2016216393A (ja) アレルギー疾患の予防改善剤
AU2014243769A1 (en) Prebiotic composition and method of its use
TW201244721A (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
TW201233340A (en) Human milk oligosaccharides for modulating inflammation
US20080132466A1 (en) Blood Cholesterol Reducing Oral Composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13854674

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: IDP00201503704

Country of ref document: ID

122 Ep: pct application non-entry in european phase

Ref document number: 13854674

Country of ref document: EP

Kind code of ref document: A1